Responses
Clinical/translational cancer immunotherapy
Original research
FXa-mediated PAR-2 promotes the efficacy of immunotherapy for hepatocellular carcinoma through immune escape and anoikis resistance by inducing PD-L1 transcription
Compose a Response to This Article
Other responses
No responses have been published for this article.
